A Study to Evaluate Pulmonary Vascular Complications of Liver Disease 3 (PVCLD3)

Overview

About this study

The purpose of this study is toexamine whether increased sphingosine 1 phosphate : ceramide ratio and circulating bile acids are associated with HPS in patients with advanced liver disease.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Please contact the study team to discuss whether or not you are eligible to participate in a study.

Inclusion Criteria:

  • Chronic portal hypertension from intrinsic liver disease or portal vein disease, documented by clinical history or liver biopsy.
  • Referral for evaluation for liver transplantation (LT) or portopulmonary hypertension (or a known diagnosis of portopulmonary hypertension).
  • Informed consent.
  • Age ≥ 18 years old.

Exclusion Criteria

  • Active infection.
  • Active or recent (< 2 weeks) gastrointestinal bleeding.
  • Lung transplant or LT recipients.
  • Pregnant women.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Michael Krowka, M.D.

Open for enrollment

Contact information:

Adam Miller B.S.

127or7768147

Miller.Adam@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20454549

Mayo Clinic Footer